Transformative AI in healthcare sits at the crossroads of powerful themes investors are watching today: pressure to improve efficiency, closer scrutiny on costs, and fast progress in data driven tools. While central banks and bond markets react to inflation and energy shocks, AI healthcare stocks tap into a different story, one built around diagnostics, personalized treatment and faster research. This article highlights 3 of the best stocks from our Transformative AI Healthcare Stocks screener. The screener is designed to help you focus on companies aiming to use AI to improve accuracy, access and affordability in global health systems.

Butterfly Network (BFLY)

Overview: Butterfly Network is a medical technology company that makes handheld ultrasound devices and AI powered software so clinicians can perform whole body imaging at the bedside using a single probe connected to a phone, tablet, or hospital computer. Its platform also extends into bladder scanning, veterinary applications, education tools, and enterprise software that links devices, workflows, and departments.

Operations: Butterfly Network generates around US$102.9m in revenue from providing an AI enhanced personal ultrasound solution, with about US$81.8m coming from the United States and US$21.2m from international markets.

Market Cap: US$1.9b

Butterfly Network gives investors exposure to handheld ultrasound powered by its ultrasound on chip technology and AI software such as Compass AI, which aims to make imaging more accessible and consistent across hospitals and clinics. Recent agreements that include upfront and potential milestone payments, along with guidance pointing to triple digit million annual revenue, indicate the business is pursuing multiple ways to monetize its technology. At the same time, Butterfly is still reporting losses, has a high P/S multiple, relies on higher risk external borrowing, and has seen insider share sales. Together, these factors point to elevated risk. For investors who can tolerate volatility, the combination of AI, medical devices, and licensing potential makes this company a closely watched name.

Butterfly Network sits at the intersection of AI imaging excitement and real funding risk, so before you decide how it fits into your portfolio, review the 1 key reward and 2 important warning signs (1 is major!)

Pfizer (PFE)

Overview: Pfizer is a global biopharmaceutical company that discovers, develops, manufactures and sells a wide range of prescription medicines and vaccines, covering areas such as cardiovascular disease, migraine, inflammation, rare diseases, oncology, biosimilars and sterile injectables.

Operations: Pfizer generates about US$61.9b in revenue from its Global Biopharmaceuticals Business, supported by a Segment Adjustment of roughly US$1.4b.

Market Cap: US$137.1b

Pfizer provides exposure to a broad portfolio of established drugs and vaccines, along with a sizeable pipeline in obesity and oncology, areas where new therapies and label expansions could influence its earnings mix over time. The stock trades on a modest P/E, carries a high dividend yield around 7% and appears heavily discounted on some cash flow estimates, yet faces pressure from patent expirations, earnings declines and a balance sheet that leans on external funding. For investors interested in AI supported drug discovery, obesity treatments and oncology, while keeping an eye on payout and leverage risks, Pfizer combines income potential with pipeline execution risk and may warrant closer examination.

Pfizer’s high dividend yield and modest P/E may be masking a deeper story in its drug portfolio and AI supported pipeline, so consider both perspectives through the 1 key reward and 4 important warning signs (3 are major!)

Tempus AI (TEM)

Overview: Tempus AI is a healthcare technology company that runs a data rich platform combining genomic and other lab diagnostics with clinical records and AI tools, so doctors and drug developers can make more precise decisions in cancer care and other conditions. Its products range from next generation sequencing tests and pharmacogenomic assays through to software like Lens and Next, which help life sciences customers analyze de identified patient data and design more targeted clinical trials.

Operations: Tempus AI generates about US$1.4b in revenue from its Medical Labs & Research activities, all from the United States.

Market Cap: US$10.3b

Tempus AI gives investors exposure to one of the deepest healthcare data pools in the market, with tens of millions of de identified records feeding AI models that power both diagnostics for hospitals and high margin data and application sales to large pharmaceutical companies. The company is attracting blue chip partners, such as Gilead and Bristol Myers Squibb, and recent FDA decisions around its xT CDx assay and ECG AF model support its credibility in regulated settings. However, the stock still carries funding risk, ongoing losses, and a P/S that looks expensive compared with peers. For investors interested in where AI and precision medicine intersect, the balance between this growing data moat and the unresolved profitability profile is a key consideration.

Tempus AI’s growing data moat could be masking where the real inflection sits in its story, so weigh the upside and funding risk through the 2 key rewards and 2 important warning signs

The three stocks in this article are just a starting sample, and the full Transformative Artificial intelligence (AI) Healthcare Stocks screener on Simply Wall St surfaced 37 more companies with equally compelling AI in healthcare narratives through the Transformative Artificial intelligence (AI) Healthcare Stocks screener.

Identify and analyze the specific catalysts that matter to you, from AI driven diagnostics and personalized medicine to hospital efficiency and remote monitoring, so you can focus on the highest conviction opportunities that best fit your own approach.

Take Control of Your Investment Journey

If Tempus AI or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond Healthcare?

Markets move fast and tomorrow’s breakout ideas often start flying under the radar for now, before the crowd catches on. Scan these fresh stock shortlists and get in early.

• Spot cash rich companies that aim to ride future upswings by screening a curated list of solid balance sheet and fundamentals (47 results) that is ready for the next leg of momentum.
• Zero in on income opportunities by reviewing a hand picked 9 dividend fortresses that could keep paying while other payouts are dropping or stalling.
• Track the backbone of AI rollouts by checking a focused 52 AI infrastructure stocks that is positioned to benefit as data demand builds and capacity tightens.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.